|
|
Office Locations:
|
505 Fifth Avenue, 18th Floor
New York, NY 10017
Phone: 212-402-6925
| | |
|
|
|
- Expansion
- Growth
- Middle Market
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Athyrium is a specialized asset management company which advises funds with over $3.7 billion in committed capital. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium focuses on investment opportunities in the global healthcare sector broadly defined to include pharmaceuticals, biologics, biotechnology, specialty and generic pharmaceuticals, medical devices and products, laboratory and diagnostics products and services, healthcare services, and healthcare information technology. In general, Athyrium: seeks to invest $25 million to $150 million per transaction with the ability to scale-up opportunistically on select investments; invests in both public and select private companies across all geographies; and prefers to invest in commercial-stage companies that sell products that have highly compelling clinical data and are cost effective.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
